DUPIXENT is the only biologic that inhibits
IL-4 and IL-13 signaling, two of the
sources that mediate airway remodeling
and lung function, respectively1,2,a
a The mechanism of dupilumab action in asthma
has not been established.
IL-13 signaling promotes2-4:
Mucus hypersecretion
Airway smooth muscle hypertrophy
Epithelial barrier disruption
DUPIXENT is indicated as an add-on maintenance
treatment in patients with moderate-to-severe asthma
aged 12 years and older with an eosinophilic phenotype
or with oral corticosteroid dependent asthma. Limitation
of Use
: DUPIXENT is not indicated for the relief of acute
bronchospasm or status asthmaticus.
Choose dual inhibition to benefit
your appropriate asthma patients
FIND OUT MORE